Treatment
Share your love
MRI study links glymphatic system dysfunction to idiopathic intracranial hypertension | Ophthalmology Times
(Image Credit: AdobeStock/littlewolf1989) A press release from Mass General Brigham, Boston, reported that the so-called “waste clean-up system,” in the brain, ie, the glymphatic system, is affected negatively by elevated intracranial pressure. This system helps circulate fluid in the brain…
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials | Ophthalmology Times
FDA approval of YUVEZZI marks the first dual-agent, daily eye drop option for adults seeking non-invasive presbyopia treatment. (Image credit: Ophthalmology Times) The FDA has approved a fixed-dose ophthalmic combination of carbachol and brimonidine tartrate (YUVEZZI; Tenpoint Therapeutics) for the…
FDA Type C meeting supports phase 2b/3 pathway for urcosimod in neuropathic corneal pain | Ophthalmology Times
(Image Credit: AdobeStock/OlegKachura) Editor’s Note: This content was generated with the assistance of AI. A US Food and Drug Administration (FDA) Type C meeting has clarified key elements of the late-phase development pathway for urcosimod, an investigational topical therapy for neuropathic…
FDA approves NDA labeling supplement allowing re-administration of iDose TR | Ophthalmology Times
The US Food and Drug Administration has approved an NDA labeling supplement from Glaukos enabling the re-administration of iDose TR (travoprost intracameral implant) using a repeat treatment protocol. According to the company, under the updated labeling for iDose TR, physicians may now re-administer iDose…
Belite Bio completes enrollment in phase 2/3 DRAGON II trial for STGD1 | Ophthalmology Times
(Image Credit: AdobeStock/khunkornStudio) Belite Bio has completed enrollment in its phase 2/3 DRAGON II clinical trial evaluating tinlarebant for the treatment of Stargardt disease type 1 (STGD1). Tinlarebant is a novel oral therapy intended to reduce the accumulation of vitamin…
Myra Vision treats first patient in ADAPT trial of Calibreye TGT Surgical System | Ophthalmology Times
(Image Credit: AdobeStock/andrew_shots) Myra Vision has treated the first patient in its ADAPT clinical study evaluating the Calibreye TGT Surgical System in patients with glaucoma. The ADAPT trial is a prospective, multicenter, nonrandomized, open-label study enrolling 70 refractory glaucoma patients…
Cloudbreak Pharma completes FDA end-of-phase-2 meeting for CBT-004 in pinguecula | Ophthalmology Times
(Image Credit: AdobeStock/pressmaster) Cloudbreak Pharma and the US Food and Drug Administration have completed an end-of-phase 2 meeting regarding the late-stage development of CBT-004 for the treatment of pinguecula. According to the company, this meeting helped to provide a “clear…
FDA clears Novaliq’s Investigational New Drug application for NOV05 | Ophthalmology Times
(Image Credit: AdobeStock/Stock Contributor) The US Food and Drug Administration (FDA) has cleared Novaliq’s Investigational New Drug (IND) application for NOV05, enabling the initiation of the EYETAC phase II clinical trial (NCT07285070) in patients with non-infectious anterior uveitis (NIAU). NOV05,…
Dr. Mali’s top 5 predictions in ophthalmology for 2026 | Ophthalmology Times
From artificial intelligence to retinal care and postoperative protection, Joshua Mali, MD, FASRS, offers five predictions shaping ophthalmology in 2026. (Image credit: AdobeStock/Sam Efendi) It’s that exciting time of the year again when I reveal my top 5 predictions in…
Moorfields study reveals sharp rise in glaucoma burden across the UK | Ophthalmology Times
(Image Credit: AdobeStock/Vitalii) A recent press release issued by Moorfields Eye Hospital announced startling glaucoma prevalence data based on a new study1 published in the British Journal of Ophthalmology. The data estimate that the prevalence of glaucoma currently is almost…